Compare · NVO vs ZBIO
NVO vs ZBIO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zenas BioPharma Inc. (ZBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZBIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 104.2x ZBIO ($1.62B).
- Over the past year, NVO is down 30.0% and ZBIO is up 4.5% - ZBIO leads by 34.6 points.
- ZBIO has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for ZBIO).
- Company
- Novo Nordisk A/S
- Zenas BioPharma Inc.
- Price
- $39.23+2.88%
- $25.40+2.42%
- Market cap
- $168.79B
- $1.62B
- 1M return
- -5.98%
- -21.44%
- 1Y return
- -30.04%
- +4.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest ZBIO
- SEC Form 8-K filed by Zenas BioPharma Inc.
- Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
- Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
- Zenas BioPharma to Host Virtual R&D Event
- Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-3ASR filed by Zenas BioPharma Inc.
- SEC Form S-8 filed by Zenas BioPharma Inc.
- SEC Form SCHEDULE 13G filed by Zenas BioPharma Inc.
- Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event